Physician profile
Robert Farron
NPI 1245237098
$6,042.35
in general payments reported to CMS, 2019-2025
22 companies · $686 in 2025
The $686 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $1,009 · 2021: $1,323 · 2022: $718 · 2023: $749 · 2024: $853 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,288.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,342.94 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $1,172.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $981.18 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $563.31 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.74 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Sanofi US Services INC. | $350.00 | 2021 | |
| Exact Sciences Corporation | $316.92 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $203.84 | 2019-2021 | |
| Genzyme Corporation | $180.00 | 2020 | |
| Amgen INC. | $131.44 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $72.61 | 2019-2023 | |
| Phadia US INC. | $62.93 | 2019-2024 | Immunocap |
| Sanofi Pasteur INC. | $44.44 | 2019 | |
| Paratek Pharmaceuticals, INC. | $42.20 | 2021-2022 | |
| Dexcom, INC. | $26.09 | 2025 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $24.20 | 2024 | Skyclarys |
| Biohaven Pharmaceutical Holding Company LTD. | $23.06 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $21.12 | 2020 | |
| Xeris Pharmaceuticals, INC. | $19.61 | 2025 | Gvoke Hypopen |
| Abbott Laboratories | $19.59 | 2021 | |
| Amarin Pharma, INC. | $17.19 | 2019 | |
| Astellas Pharma US INC | $15.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Farron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.